- Trials with a EudraCT protocol (19)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
19 result(s) found for: Concentration gradient.
Displaying page 1 of 1.
EudraCT Number: 2020-002130-33 | Sponsor Protocol Number: ZILU-COV | Start Date*: 2020-05-26 |
Sponsor Name:University Hospital Ghent | ||
Full Title: A prospective, randomized, open-label, interventional study to investigate the efficacy of complement C5 inhibition with Zilucoplan® in improving oxygenation and short- and long-term outcome of COV... | ||
Medical condition: COVID-19 patients with acute hypoxic respiratory failure. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-004624-21 | Sponsor Protocol Number: AC-055-404 | Start Date*: 2015-04-13 | |||||||||||
Sponsor Name:ACTELION Pharmaceuticals Ltd. | |||||||||||||
Full Title: A randomized, double-blind, placebo-controlled, prospective, multicenter, parallel group study to assess the safety and efficacy of macitentan in patients with portopulmonary hypertension | |||||||||||||
Medical condition: Portopulmonary hypertension | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) CZ (Completed) ES (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-004031-12 | Sponsor Protocol Number: AC15007 | Start Date*: 2017-01-05 | |||||||||||
Sponsor Name:University of Edinburgh [...] | |||||||||||||
Full Title: Serelaxin To Lower Portal Pressure in Patients with Cirrhosis and Portal Hypertension (STOPP) | |||||||||||||
Medical condition: Portal hypertension in patients with liver cirrhosis. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-000704-25 | Sponsor Protocol Number: PASP01 | Start Date*: 2017-02-28 |
Sponsor Name:Queen Mary University of London | ||
Full Title: Prevention of Aortic Stenosis Pilot Trial | ||
Medical condition: Aortic Stenosis. It is caused by the build-up of calcium phosphate crystals on the aortic valve (aortic sclerosis). Progressive valve narrowing (stenosis) leads to symptoms (chest pain, syncope or ... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-002785-12 | Sponsor Protocol Number: CY6021 | Start Date*: 2020-05-25 | |||||||||||
Sponsor Name:Cytokinetics, Inc. | |||||||||||||
Full Title: A multi-center, randomized, double-blind, placebo-controlled, dose-finding study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of CK-3773274 in adults with symptomati... | |||||||||||||
Medical condition: obstructive hypertrophic cardiomyopathy (oHCM) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) GB (GB - no longer in EU/EEA) NL (Ongoing) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-005310-19 | Sponsor Protocol Number: PI-0697-2012 | Start Date*: 2013-06-05 |
Sponsor Name:FUNDACION PARA LA INVESTIGACIÓN BIOSANITARIA DE ANDALUCIA ORIENTAL_ FPA | ||
Full Title: Double-blind randomized clinical trial to evaluate the efficacy and safety of levosimendan as preischemic myocardial conditioner in pediatric cardiac surgery | ||
Medical condition: Children aged 1 month to 14 years in the health area of the province of Granada who will be undergoing heart surgery with a clinical high risk of developing acute heart failure after surgery, treat... | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2012-005330-10 | Sponsor Protocol Number: 987654321 | Start Date*: 2013-03-14 |
Sponsor Name:Erasmus University Medical Centre | ||
Full Title: Maternal pharmacokinetics and pharmacodynamics of nicardipine (iv) during treatment of severe hypertension in pregnancy. | ||
Medical condition: Pregnant patients with preeclampsia (hypertension and protein/creatinine ratio ≥ 30mg/mmol or ≥ 300mg protein/24hours) complicated with severe hypertension (systolic bloodpressure ≥ 160mmHg and/or ... | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2021-001360-20 | Sponsor Protocol Number: MINECRAFT | Start Date*: 2021-07-29 | |||||||||||
Sponsor Name:FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO | |||||||||||||
Full Title: MINECRAFT Study: MINEralcorticoid receptor antagonism with CanRenone As eFfective Treatment in moderate to severe ARDS in COVID-19, a phase 2 clinical trial. | |||||||||||||
Medical condition: SARS-CoV2 infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-002133-37 | Sponsor Protocol Number: COR-2012-01 | Start Date*: 2014-11-17 | |||||||||||
Sponsor Name:Cortendo AB | |||||||||||||
Full Title: An Open Label Study to Assess the Safety and Efficacy of COR—003 (2S, 4R-Ketoconazole) in the Treatment of Endogenous Cushing’s Syndrome | |||||||||||||
Medical condition: Endogenous Cushing's syndrome (CS) or Cushing's disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) ES (Completed) BE (Completed) NL (Completed) SE (Completed) DK (Completed) DE (Completed) IT (Completed) BG (Completed) CZ (Completed) HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2023-000018-16 | Sponsor Protocol Number: OZA22/IM047-048 | Start Date*: 2023-04-19 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA UNIVERSITARIA INTEGRATA VERONA | |||||||||||||
Full Title: Effect of ozanimod on meningeal inflammation and glial activation in Multiple Sclerosis: one year phase 4 experimental study | |||||||||||||
Medical condition: Relapsing Multiple Sclerosis (relapsing-remitting, relapsing-progressive) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-001853-15 | Sponsor Protocol Number: NL61830 | Start Date*: 2018-07-11 |
Sponsor Name:Leiden University Medical Center | ||
Full Title: An explorative study for halting inflammation in patients with emphysema by intravenous administration of autologous bone marrow derived mesenchymal stromal cells. | ||
Medical condition: Pulmonary emphysema | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2008-001035-35 | Sponsor Protocol Number: CSPP100A2252 | Start Date*: 2009-06-04 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: a double blind, double dummy, randomized, multicenter, parallel group study to evaluate the Effects of aliSkiren, ramipril and combination treatment on plasma Concentration of Angiotensin II in Pat... | |||||||||||||
Medical condition: hypertension | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-002341-22 | Sponsor Protocol Number: GLINOX-01 | Start Date*: 2014-07-11 | |||||||||||
Sponsor Name:Medizinische Universität Graz; Universitätsklinik für InnereMedizin; Abteilung für Endokrinologie und Stoffwechsel | |||||||||||||
Full Title: Evaluation of the Effect of Glucagon Solutions on the Glucose Concentration at the Subcutaneous Administration Site in Type 1 Diabetic Patients. | |||||||||||||
Medical condition: Diabetes Mellitus type 1 | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-004604-19 | Sponsor Protocol Number: CAR-ERA | Start Date*: 2014-08-06 | |||||||||||
Sponsor Name:Heinrich-Heine-Universität Düsseldorf | |||||||||||||
Full Title: Delayed Gadolinium-enhanced Magnetic resonance Imaging (MRI) of Cartilage - A pilot study to measure the effect of Adalimumab plus Methotrexat (MTX) versus Placebo plus MTX on cartilage in early rh... | |||||||||||||
Medical condition: patients with early progressive rheumatoid arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-004287-30 | Sponsor Protocol Number: LAL-CL06 | Start Date*: 2014-06-19 | |||||||||||
Sponsor Name:Alexion Pharmaceuticals inc | |||||||||||||
Full Title: A Multicenter, Open-Label Study of Sebelipase Alfa in Patients with Lysosomal Acid Lipase Deficiency | |||||||||||||
Medical condition: Lysosomal Acid Lipase Deficiency (LALD) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) ES (Completed) GB (Completed) IT (Prematurely Ended) DE (Completed) BE (Completed) HR (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-004128-35 | Sponsor Protocol Number: CAEB071A2207 | Start Date*: 2007-03-06 |
Sponsor Name:Novartis Pharma Services AG | ||
Full Title: A 12-month open-label, randomized, multicenter, sequential cohort, dose finding study to evaluate the efficacy, safety and tolerability of oral AEB071 versus tacrolimus® in combination with myforti... | ||
Medical condition: Evaluation of the efficacy and safety of AEB071 in de novo CNI free regimen for prevention of rejection in solid organ transplantation. Combination of AEB071 with a well established, effective ad... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Prematurely Ended) DE (Prematurely Ended) GB (Prematurely Ended) BE (Completed) ES (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2021-001088-26 | Sponsor Protocol Number: MN42928 | Start Date*: 2021-12-21 | |||||||||||
Sponsor Name:F. HOFFMANN - LA ROCHE LTD. | |||||||||||||
Full Title: SAKURABONSAI: CLINICAL, IMAGING AND BIOMARKER OPEN-LABEL STUDY IN NEUROMYELITIS OPTICA SPECTRUM DISORDER (NMOSD) WITH SATRALIZUMAB AS AN INTERVENTION | |||||||||||||
Medical condition: Neuromyelitis Optica Spectrum Disorder (NMOSD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) FR (Completed) DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002834-59 | Sponsor Protocol Number: SNFCT2015-05 | Start Date*: 2016-11-28 | |||||||||||||||||||||
Sponsor Name:Sanifit Therapeutics S.A. | |||||||||||||||||||||||
Full Title: A double-blind, randomised, placebo-controlled study to assess the effect of SNF472 on progression of cardiovascular calcification on top of standard of care in end-stage-renal-disease (ESRD) patie... | |||||||||||||||||||||||
Medical condition: Cardiovascular calcification in blood vessels in end-stage-renal-disease (ESRD) patients on haemodialysis (HD). | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: GB (Completed) ES (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2009-014260-19 | Sponsor Protocol Number: CH/2009/3187 | Start Date*: 2010-01-29 | |||||||||||||||||||||||||||||||
Sponsor Name:University Hospital Bristol NHS Foundation Trust | |||||||||||||||||||||||||||||||||
Full Title: A feasibility study of adding xenon to cooling therapy in babies at high risk of brain injury following poor condition at birth | |||||||||||||||||||||||||||||||||
Medical condition: Neonatal hypoxia-ischaemia (HI). There is no exact MedDRA term for this. The closest MedDRA terms matching this are neonatal asphyxia and neonatal hypoxia. | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Newborns, Under 18 | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: GB (Completed) | |||||||||||||||||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
